Related references
Note: Only part of the references are listed.IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Sue Han et al.
BRITISH JOURNAL OF CANCER (2020)
Brain immunology and immunotherapy in brain tumours
John H. Sampson et al.
NATURE REVIEWS CANCER (2020)
5-ALA and FDA approval for glioma surgery
Constantinos G. Hadjipanayis et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis
Debra A. Goldman et al.
JOURNAL OF NEUROSURGERY (2018)
Residual enhancing disease after surgery for glioblastoma: evaluation of practice in the United Kingdom
Ruichong Ma et al.
NEURO-ONCOLOGY PRACTICE (2018)
Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis
Myra E. van Linde et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Anna C. Filley et al.
ONCOTARGET (2017)
Recurrence Pattern Analysis of Primary Glioblastoma
Marion Rapp et al.
WORLD NEUROSURGERY (2017)
Usefulness of Reintervention in Recurrent Glioblastoma: An Indispensable Weapon for Increasing Survival
Juan Delgado-Fernandez et al.
WORLD NEUROSURGERY (2017)
Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection
Florian Ringel et al.
NEURO-ONCOLOGY (2016)
Benefit of tumor resection for recurrent glioblastoma
Johanna Quick et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity
Mark E. Oppenlander et al.
JOURNAL OF NEUROSURGERY (2014)
The epidemiology of glioma in adults: a state of the science review
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2014)
Standards of care for treatment of recurrent glioblastoma-are we there yet?
Michael Weller et al.
NEURO-ONCOLOGY (2013)
Early Re-Do Surgery for Glioblastoma Is a Feasible and Safe Strategy to Achieve Complete Resection of Enhancing Tumor
Philippe Schucht et al.
PLOS ONE (2013)
Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?
Patrick G. Morris
ANTI-CANCER DRUGS (2012)
Impact of extent of resection for recurrent glioblastoma on overall survival Clinical article
Orin Bloch et al.
JOURNAL OF NEUROSURGERY (2012)
Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme
R. Helseth et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study
James J. Vredenburgh et al.
ONCOLOGIST (2010)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Iatrogenic immunosuppression in patients with newly diagnosed high-grade gliomas
S. A. Grossman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials
Kathryn A. Carson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients
J. -F. Mineo et al.
ACTA NEUROCHIRURGICA (2007)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
